Every 10-Q that CVS Health Corporation (CVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVS filings page.
CVS Health Corporation reported higher quarterly earnings on modest revenue growth. For the three months ended March 31, 2026, total revenues rose to $100.4 billion from $94.6 billion a year earlier, driven mainly by growth in pharmacy products and premiums across its Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments.
Net income attributable to CVS Health increased to $2.94 billion from $1.78 billion, with diluted earnings per share rising to $2.30 from $1.41. Operating income improved to $4.68 billion, reflecting higher operating margins and fewer large one‑time charges than in the prior year.
Cash and cash equivalents were $9.54 billion as of March 31, 2026, up from $8.45 billion at year-end 2025, while net cash provided by operating activities was $4.25 billion. Long-term debt remained sizable at about $60.5 billion, but total shareholders’ equity increased to $77.6 billion, supported by retained earnings growth and consistent quarterly dividends of $0.665 per share.
CVS Health (CVS) reported a Q3 2025 net loss driven by a non-cash impairment. Total revenues rose to $102.871B from $95.428B a year ago, led by higher product sales and premiums. However, a $5.725B goodwill impairment and higher operating costs pushed operating income to a loss of $3.207B versus income of $832M last year. Net loss attributable to CVS Health was $3.975B (diluted EPS -$3.13), compared with net income of $87M (EPS $0.07) in Q3 2024.
Year to date, revenues reached $296.374B, while net income attributable to CVS Health was a loss of $1.175B (EPS -$0.93). The quarter included a $483M gain on the deconsolidation of a subsidiary and $632M of net investment income. Cash from operations for the first nine months was $7.249B, essentially flat year over year. On the balance sheet, cash and cash equivalents were $9.098B, goodwill declined to $85.478B, and total debt (short-term, current portion of long-term, and long-term) remained significant. As of October 22, 2025, shares outstanding were 1,269,432,485.